In March 2014, Pragma acquired Moxatag from Shionogi and has been working to make the product available in time for the upcoming cold and flu season.
Pragma spokesperson said: "Amoxicillin is the gold standard in treating strep pharyngitis.
"Simplifying the dosing regimen is a no brainer. Greater convenience to help patient compliance is key to ensuring effective antibiotic therapy."
Seperately, Pragma has selected Fera Pharmaceuticals to manage the sales and marketing of Moxatag.
Currently, Moxatag is approved to treat tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in adult and pediatric patients 12 years of age or older.
Amoxicillin exerts its bactericidal action against susceptible organisms during the stage of multiplication and it acts through the inhibition of biosynthesis of cell wall mucopeptide.